Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Curevac N V Ord (0A9E) Regulatory News

Date Source Headline
28th May 2024 12:01 pm EQS CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
23rd May 2024 12:01 pm EQS CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
24th Apr 2024 12:08 pm EQS CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
24th Apr 2024 12:04 pm EQS CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
24th Apr 2024 12:01 pm EQS CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
18th Apr 2024 12:01 pm EQS CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
16th Apr 2024 12:02 pm EQS CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
4th Apr 2024 12:02 pm EQS CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
5th Jan 2024 12:02 pm EQS CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
19th Dec 2023 2:24 pm EQS CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
14th Nov 2023 12:02 pm EQS CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
1st Nov 2023 12:02 pm EQS CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
28th Sep 2023 12:02 pm EQS CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
12th Sep 2023 12:01 pm EQS CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
17th Aug 2023 12:01 pm EQS CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
1st Aug 2023 12:01 pm EQS CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
14th Jul 2023 12:01 pm EQS CureVac Announces Update to the Management Team
13th Jul 2023 12:01 pm EQS CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
20th Jun 2023 12:06 pm EQS CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma
20th Jun 2023 12:01 pm EQS CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
19th Jun 2023 4:31 pm EQS CureVac Announces Voting Results of General Meeting
30th May 2023 12:01 pm EQS CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
19th May 2023 12:01 pm EQS CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
8th May 2023 12:01 pm EQS CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
25th Apr 2023 12:01 pm EQS CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update
18th Apr 2023 12:01 pm EQS CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023
28th Mar 2023 9:06 pm EQS CureVac Announces Voting Results of Extraordinary General Meeting
10th Feb 2023 9:05 pm EQS CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
8th Feb 2023 1:04 am EQS CureVac Announces Pricing of Upsized Public Offering of Common Shares
6th Feb 2023 9:06 pm EQS CureVac Announces Proposed Public Offering of Common Shares
1st Feb 2023 12:00 pm EQS CureVac Welcomes Myriam Mendila as New Chief Development Officer
31st Jan 2023 1:13 pm EQS CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis®
30th Jan 2023 12:02 pm EQS CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
9th Jan 2023 12:00 pm EQS CureVac Appoints Alexander Zehnder as CEO From April 1, 2023
6th Jan 2023 12:01 pm EQS CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs
14th Dec 2022 9:05 pm EQS CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program
16th Nov 2022 12:00 pm EQS CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update
11th Nov 2022 12:00 pm EQS CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102
10th Nov 2022 12:00 pm EQS CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022
18th Aug 2022 12:06 pm EQS CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update
FTSE 100 Latest
Value8,605.35
Change62.79